Applied Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Shoshana Shendelman

Algemeen directeur

US$9.5m

Totale compensatie

Percentage CEO-salaris	6.6%
Dienstverband CEO	8.8yrs
Eigendom CEO	3.9%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	7.8yrs

Recente managementupdates

Recent updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Nov 15

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Sep 18

Applied Therapeutics: Pushing Towards FDA Approval

Sep 04

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Aug 01

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24

Applied Therapeutics EPS misses by $0.21

Nov 12

Analyse CEO-vergoeding

Hoe is Shoshana Shendelman's beloning veranderd ten opzichte van Applied Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$187m
Jun 30 2024	n/a	n/a	-US$161m
Mar 31 2024	n/a	n/a	-US$194m
Dec 31 2023	US$9m	US$630k	-US$120m
Sep 30 2023	n/a	n/a	-US$97m
Jun 30 2023	n/a	n/a	-US$73m
Mar 31 2023	n/a	n/a	-US$70m
Dec 31 2022	US$3m	US$588k	-US$83m
Sep 30 2022	n/a	n/a	-US$95m
Jun 30 2022	n/a	n/a	-US$105m
Mar 31 2022	n/a	n/a	-US$105m
Dec 31 2021	US$2m	US$588k	-US$106m
Sep 30 2021	n/a	n/a	-US$102m
Jun 30 2021	n/a	n/a	-US$104m
Mar 31 2021	n/a	n/a	-US$106m
Dec 31 2020	US$5m	US$578k	-US$94m
Sep 30 2020	n/a	n/a	-US$88m
Jun 30 2020	n/a	n/a	-US$69m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$12m	US$550k	-US$46m
Sep 30 2019	n/a	n/a	-US$35m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$1m	US$500k	-US$17m

Compensatie versus markt: De totale vergoeding ($USD 9.49M ) Shoshana } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.20M ).

Compensatie versus inkomsten: De vergoeding van Shoshana is gestegen terwijl het bedrijf verliesgevend is.

CEO

Shoshana Shendelman (45 yo)

8.8yrs

Tenure

US$9,493,213

Compensatie

Dr. Shoshana Shendelman, PhD, has been Director of Applied Therapeutics Inc. since January 2016. Prior to founding Applied, she founded Clearpoint Strategy Group, a boutique life science consulting firm, w...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Shoshana Shendelman	Chair of the Board of Directors	no data	US$9.49m	3.91% $ 42.9m
Les Funtleyder	CFO, Principal Financial Officer & Independent Director	less than a year	US$675.15k	0.078% $ 852.6k
Riccardo Perfetti	Chief Medical Officer	6.3yrs	US$3.04m	0.14% $ 1.6m
Constantine Chinoporos	COO & Chief Business Officer	less than a year	geen gegevens	geen gegevens
Catherine Thorpe	Chief Accounting Officer	1.4yrs	geen gegevens	geen gegevens
Corwin Hooks	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens

1.0yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van APLT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Shoshana Shendelman	Chair of the Board of Directors	8.8yrs	US$9.49m	3.91% $ 42.9m
Les Funtleyder	CFO, Principal Financial Officer & Independent Director	8.4yrs	US$675.15k	0.078% $ 852.6k
Joel Marcus	Independent Director	7.8yrs	US$85.65k	0.39% $ 4.3m
Jay Skyler	Independent Director	5.6yrs	US$92.53k	0.017% $ 188.6k
Lawrence Steinman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Teena Lerner	Lead Independent Director	7.7yrs	US$88.78k	0.052% $ 569.8k
Stacy Kanter	Independent Director	5.5yrs	US$94.40k	0.054% $ 594.0k
Gregg Stone	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Donald Landry	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Donald D'Amico	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Roy Freeman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Roxana Mehran	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

7.8yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van APLT wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).

Applied Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Chair of the Board of Directors recently sold US$1.7m worth of stock

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Insufficient new directors

Recent updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

Applied Therapeutics: Pushing Towards FDA Approval

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold US$1.7m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Consensus EPS estimates fall by 36%

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

New major risk - Shareholder dilution

Consensus EPS estimates fall by 13%

Consensus revenue estimates fall by 27%

New major risk - Financial position

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Consensus revenue estimates decrease by 21%

Consensus revenue estimates increase by 89%

Consensus revenue estimates increase by 1,731%

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Price target increased by 27% to US$15.00

Insufficient new directors

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics, Inc. Announces Positive Data Trend in AT-007 Action-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

Price target increased to US$16.50

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell 2000 Growth Index

Applied Therapeutics Receives Orphan Medicinal Product Designation from the Ema for AT-007 for Treatment of Galactosemia

Insufficient new directors

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Price target decreased to US$12.10

Applied Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$13.63

Price target decreased to US$28.80

Applied Therapeutics, Inc. Announces Executive Changes

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Price target increased to US$39.20

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Applied Therapeutics, Inc Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

Price target decreased to US$34.40

Price target increased to US$49.40

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Chair of the Board of Directors recently bought US$145k worth of stock

Chief Medical Officer notifies of intention to sell stock

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Chief Medical Officer exercised options and sold US$714k worth of stock

Chief Medical Officer exercised options and sold US$97k worth of stock

Price target decreased to US$44.50

Applied Therapeutics Grants Fast Track Designation by FDA for AT-007 for Galactosemia

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

CFO & Head of Business Development recently sold US$108k worth of stock

Chief Commercial Officer recently sold US$53k worth of stock

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2025